Enables access to a broad range of
biodiversity to find unique antibodies against challenging
targets
EMERYVILLE, Calif., Nov. 18,
2022 /PRNewswire/ -- Berkeley Lights, Inc.
(NASDAQ: BLI), a leader in digital cell biology, today announced
the launch of the Opto® Memory B Discovery Rabbit
workflow, expanding the diversity of antibodies customers can
discover on the Beacon® platform.
The new workflow enables rapid, automated generation of
antigen-specific, functional monoclonal antibodies from rabbit
memory B cells, building on prior workflows that used mouse plasma
B cell samples. This workflow broadens Berkeley Lights' market
opportunity beyond mouse workflows, enabling discovery of
high-value rabbit antibodies that are well-suited for
therapeutics, diagnostics and research reagents. While there are
currently no robust markers to enrich rabbit plasma B cells, rabbit
memory B cells can be readily obtained from blood and easier to
source and handle than plasma B cells.
Using the Opto Memory B Discovery Rabbit workflow, Berkeley
Lights estimates the Beacon platform can:
- Screen approximately 15,000 to 60,000 single cells per
workflow, depending on chip selection and number of chips used per
workflow;
- Identify hundreds to thousands of antigen-specific hits per
workflow; and
- Recover high-quality antibody sequences for the majority of
discovered hits
"We are continuing to advance our workflows in antibody
discovery to help our customers find high-value molecules against
the most difficult targets," said Siddhartha Kadia, Ph.D., chief
executive officer of Berkeley Lights. "This new workflow targeting
rabbit memory B cells expands the diversity of antibodies that our
customers can discover on the Beacon platform and offers a superior
alternative to traditional methods, which are more costly and
time-consuming. Using this technology, our customers will be able
to rapidly screen rabbit memory B cells for discovery, recovery,
and sequencing of functionally characterized antibodies in just a
single week."
About Berkeley Lights
Berkeley Lights is a leading digital cell biology company
focused on enabling and accelerating the rapid development and
commercialization of biotherapeutics and other cell-based products
for our customers. The Berkeley Lights Platform captures deep
phenotypic, functional, and genotypic information for thousands of
single cells in parallel and can also deliver the live biology
customers desire in the form of the best cells. Our platform is a
fully integrated, end-to-end solution, comprising proprietary
consumables, including our OptoSelect® chips and reagent
kits, advanced automation systems, and application software. We
developed the Berkeley Lights Platform to provide the most advanced
environment for rapid functional characterization of single cells
at scale, the goal of which is to establish an industry standard
for our customers throughout their cell-based product value
chain.
Forward-Looking
Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Berkeley Lights
or its products, they are forward-looking statements reflecting the
current beliefs and expectations of management. Such
forward-looking statements involve substantial known and unknown
risks and uncertainties that relate to future events, and actual
results and product performance could differ significantly from
those expressed or implied by the forward-looking statements.
Berkeley Lights undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties relating to the Company's growth and continual
evolution see the statements in the "Risk Factors" sections, and
elsewhere, in our filings with the U.S. Securities and Exchange
Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/berkeley-lights-accelerating-antibody-discovery-with-launch-of-rabbit-memory-b-cell-workflow-301682701.html
SOURCE Berkeley Lights, Inc.